Background Heparin-induced thrombocytopenia is a relatively uncommon but severe sideeffect of heparin therapy. Heparin-induced IgG antibody has been elucidated to be the main isotype and the most pathogenic antibody in the pathophysiology. As affected patients are at high risk of developing thrombotic events, con®rmation of the clinical diagnosis and avoidance of heparin re-exposure are important and desirable.
Introduction
For more than 50 years, heparin has been used to prevent and treat venous and arterial thrombotic diseases. Heparininduced thrombocytopenia (HIT) is identi®ed as a common cause of drug-induced thrombocytopenia, with a frequency of 5±10% [1±3] . There are two types of HIT [1, 2] . HIT type I is thought to be related to a direct proaggregatory effect of heparin on platelets. This type usually has little clinical impact; heparin therapy is accompanied by only a modest decline in platelet count within the ®rst days of treatment. The patient does not develop thromboembolic complications. HIT type II is a less common but severe immune-mediated complication of heparin therapy [4] . It is characterized by a progressive decrease in the platelet count, usually below 100´10 9 L
À1
and high risk of developing thromboembolic complications. HIT type II patients generate heparin-induced antibodies (HI-Abs), most frequently of IgG isotype, after 5 or more days of continuous heparin administration [2,5±8] . If the patient is re-exposed to heparin, thrombocytopenia may occur within hours or a few days [1±3] . The diagnosis of HIT type II may be dif®cult to make based on clinical observations only, particularly when other causes of thrombocytopenia are present [1±3,6] . Laboratory con®rmation of the diagnosis is important and desirable. Several assays, such as the platelet aggregation test (PA) [9] and heparin-induced platelet aggregation assay (HIPA) [10] to detect heparin-induced IgG (HI-IgG), and heparinplatelet factor 4 (PF4)-induced antibody enzyme-linked immunosorbent assay (ELISA) [6] , have been developed. In vitro detection of the cross-reactivity of HI-Abs with other glycosaminoglycans, as low-molecular-weight heparin (LMWH) and danaparoid, may be helpful for the further treatment of HIT patients [10] . After switching heparin treatment to other anticoagulants, the normalization of HI-Abs is of clinical relevance, but its quantitative determination remains dif®cult. In this paper we report a sensitive and speci®c assay for the relative quantitative detection of HI-IgG with¯uorescein-labelled heparin (FITC-heparin) [11] , including an analysis on the cross-reactivities of HI-IgG with LMWH and danaparoid.
Methods

Chemicals and reagents
Nitrocellulose membranes of 0´2 mm pore size, protein A with a capacity of 9 mg of human IgG bound per mg solid, protein A±agarose gel and Tween-20 were purchased from Sigma Chemical (St Louis, MO, USA). Unfractionated heparin with an activity of 160 IU mg À1 was from Braun (Melsungen, Germany). LMWH was obtained from Pharmacia Upjohn (Erlangen, Germany) with an activity of 160 IU mg
À1
. Danaparoid sodium was supplied by N. V. Organon (Oss, The Netherlands) with an activity of 10 IU mg À1 . Unfractionated heparin was labelled with uorescein-5-isothiocyanate (FITC) as described previously [11] . The parent compound and the conjugate both had a mean molecular weight of 12 000 dalton [12] and activities of 160 IU mg
. Phosphate-buffered saline (PBS) containing phosphate buffer (0´02 mol L À1 , pH 7´2) and 0´145 mol L À1 NaCl and PBS-Tween contained PBS and 0´025% (v/v) Tween-20 were used.
Patients and samples
Clinical diagnosis of HIT type II was made according to the following criteria: heparin treatment; thrombocytopenia < 50% of the initial value; thromboembolic complication documented by objective methods; recovery of the thrombocytopenia after cessation of heparin; exclusion of other causes of thrombocytopenia [1±3, 12, 13] . Sera were collected from 81 patients with clinical suspicion of HIT type II. HIT type II was diagnosed in 38 of the 81 patients. In the other 43 patients thrombocytopenia could be explained by other causes, such as septicaemia, malignancy, etc. Five of the HIT type II samples that cross-reacted with LMWH and four samples cross-reacting with danaparoid in the HIPA were used for the cross-reactivity studies in thē uorescence Rinked immuno®ltration assay (FLIFA). Four samples without cross-reaction with danaparoid in the HIPA served as control. Non-HIT control samples were obtained from 319 normal volunteers, 38 thrombocytopenic patients (20 000±60 000 platelets mL À1 ) not receiving heparin, 56 patients receiving heparin or LMWH for more than 7 days, 41 hyperbilirubinaemic patients and 50 hyperlipidaemic patients. All serum samples were aliquoted in plastic tubes and stored at À80 8C after shock freezing in liquid nitrogen.
A positive control sample was obtained from a 42-yearold patient who presented with typical HIT type II clinical characteristics and skin necrosis upon subcutaneous heparin administration and had a positive result in HIPA [13, 14] . Serum samples from 20 healthy adults were pooled as normal serum and negative control. The studies were approved by the local University Ethics Review Committee and informed consent was obtained from each patient.
Determination of optimal concentration of FITC-heparin in HI-IgG assay
Sera from ®ve clinically and HIPA-con®rmed HIT type II patients were used for the preliminary experiments. The binding of FITC-heparin to HI-IgG was performed, as described below, with neoantigen solutions prepared by incubating FITC-heparin ranging from 0´1 to 120 IU mL À1 in normal serum.
Heparin-induced IgG (HI-IgG) assay (FLIFA)
In principle, FITC-heparin was added to normal serum to obtain the neoantigens by forming complexes with heparinbinding proteins such as PF4 [6, 7] . Protein A was absorbed on nitrocellulose membrane to immobilize HI-IgG from the patient serum sample. The immobilized HI-IgG captured FITC-labelled neoantigens and was detected bȳ uorescence emission.
The experiment was performed as follows: neoantigen solution was prepared by adding FITC-heparin in normal serum (24 IU mL À1 ) and diluted 1:50 with PBS before use; after wetting in distilled water for 5 min, nitrocellulose membrane with a pore size of 0´2 mm was ®tted on a multiscan 96-well ®ltration assay device (Easy-Titer System, PIERCE, Rockford, IL, USA); protein A immobilization, blocking, HI-IgG binding and neoantigen binding were performed by suction of 200 mL per well of the following solutions: protein A (25 mg mL À1 in PBS), PBSTween buffer, 1±10 diluted test serum or positive or negative control and diluted neoantigen solution, through the nitrocellulose membrane one after the other by vacuum pressure over 10 min; after washing three times with 200 mL of PBS per well, the nitrocellulose membrane was scanned by FluorImager 575, which was equipped with the softwarè Scanner control' and`ImageQuaNT' 4´2 for Windows NT (Molecular Dynamics, Sunnyvale, CA, USA). The relativē uorescence intensity (RFI) of each sample was determined. Samples were run in duplicate. All the data were transported to Excel 5´0 program, and the RFI ratio value was calculated as follows: RFI ratio RFI of test sample/ RFI of negative control (normal serum). Based on the results in healthy subjects, the test was considered positive at a RFI ratio of $ 1´55. For every assay a HIT type IIpositive sample and normal serum were used as positive and negative control respectively.
Cross-reactivities of HI-IgG with heparin, LMWH and danaparoid
The cross-reactivities of HI-IgG were analysed using competitive binding of FITC-heparin with unlabelled heparin (n 5), LMWH (n 5) or danaparoid (n 4). Four HIT samples that did not cross-react with danaparoid in HIPA were selected as negative control in the danaparoid cross-reaction study. The assays were performed as described above by spiking the neoantigen solution with heparin (0±2400 IU mL À1 ), or LMWH (0±6000 IU mL À1 ) or danaparoid (0±500 IU mL ±1 ).
Heparin-induced platelet activation assay (HIPA)
The HIPA was performed as described by Greinacher et al. [10] . In brief, 20 mL of patient serum, 75 mL of washed platelets (300´10 9 L À1 ), two steel spheres and 10 mL of heparin (0´2 and 100 U mL
À1
) were incubated on a magnetic stirrer for 45 min. Collagen (4 mg mL
) was used as a positive control and buffer as a negative control. Results were read visually by changes in transparency of the platelet suspension.
Results
Optimization of the HI-IgG assay
The binding of FITC-heparin to HI-IgG in HIT type II patients (n 5) was concentration dependent and saturated at 24 IU mL À1 in serum. This FITC-heparin concentration in serum was chosen for further experiments.
The reproducibility of the assay was estimated by determination of a HIT type II sample on 24 consecutive days for interassay variation and 12 times in one assay for intraassay variation. The coef®cients of variation for interassay and intra-assay were 10´40% and 4´88% respectively.
Additional tests were also performed at an optimized experimental setting. Five HIT type II serum samples were serially diluted with normal serum separately, and their RFI ratio values decreased linearly with the dilutions (r 2 0´98). IgG-depleted sera from the same ®ve HIT type II patients were prepared by protein A±agarose absorption, and all became negative with RFI ratio values as normal control (data not shown).
Sensitivity and speci®city of HI-IgG assay
In 38 of the 81 clinically suspected HIT type II patients, heparin-induced thrombocytopenia type II was con®rmed using objective documentation, whereas in the other 43 patients, other reasons for the thrombocytopenia were found. The RFI ratios of HIT type II patients (n 38), not con®rmed HIT patients (n 43), healthy volunteers (n 319), patients with thrombocytopenia of other origin (n 38), and patients receiving heparin or LMWH for treatment of thromboembolism (n 56) are given in Fig. 1 . The HIT type II group and non-HIT groups were separated with the cut-off RFI ratio of 1´55. Thirty-seven of the 38 HIT type II patients had positive results in the HI-IgG assay. Forty-two of the 43 not clinically con®rmed HIT patients had negative results (Fig. 1) . The agreement between HI-IgG assay and clinical diagnosis was r 0´974. The sensitivity and speci®city of HI-IgG assay were of 97´4% (37/38) and 97´7% (42/43), respectively [13] ( Table 1a ). The receiver operating characteristic (ROC) curve was plotted using the RFI ratio values of all the 81 clinically suspected HIT patients vs. their clinical diagnosis [15] . The HI-IgG assay demonstrated a diagnostic accuracy of 0´985 for clinically suspected HIT type II patients (Fig. 2) .
All the 81 clinically suspected HIT patients were analysed by HIPA in parallel. Thirty-six of the 38 con®rmed HIT patients had positive HIPA results. The diagnostic ef®cacy of HI-IgG assay was compared with HIPA (Table 1b) . It was shown that 35 of the 38 HI-IgG positive HIT patients were positive and 41 of the 43 HI-IgG negative HIT patients were negative in both HI-IgG and HIPA assays. Both assays showed a good correlation (r 0´938).
None of normal sera and other thrombocytopenia sera had elevated HI-IgG. Two of 56 heparin/LMWH-receiving patients had HI-IgG positive results. These two patients had RFI ratios of 1´68 and 1´75. Their RFI ratio values declined to 0´80 and 1´21 after 2±4 weeks of danaparoid treatment. Thus, HI-IgG assay had speci®cities of 100%, 100% and 96´4% for normal volunteers, patients with thrombocytopenia of other origin and patients receiving heparin or LMWH therapy, respectively. In addition, hyperbilirubinaemic samples (n 41) and hyperlipidaemic samples (n 50) were analysed. Two of the 41 hyperbilirubinaemic samples had elevated RFI ratios (1´60 and 1´68 respectively), with a false-positive rate of 4´88%. Two of the 50 hyperlipidaemic samples had RFI ratios of 1´58 and 1´78, showing a false-positive rate of 4%.
Cross-reactivities of HI-IgG with heparin, LMWH and danaparoid
All the ®ve HIT type II sera used showed cross-reactivities with heparin and LMWH (Fig. 3) . FITC-heparin was dose-dependently displaced by heparin and LMWH. Among the eight HIT type II patients in the danaparoid cross-reaction study, the four samples selected with negative danaparoid cross-reaction in HIPA had no crossreactivity with danaparoid in the HI-IgG assay too; FITC-heparin was not displaced by increasing danaparoid concentrations (Fig. 4) . Three of the other four samples, which were selected because of positive danaparoid crossreaction in HIPA, showed FITC-heparin binding displaced by danaparoid in a concentration-dependent manner and had positive cross-reaction results in the HI-IgG assay (Fig. 4) . Another sample had no danaparoid binding and was negative in HI-IgG cross-reaction assay (individual data in Fig. 4) . In fact, this patient was treated with danaparoid for 2 weeks, and the HIPA assay became negative. [5, 7, 8, 17, 18] . As the diagnosis of HIT type II is dif®cult to make on clinical grounds alone, several laboratory assays were described for the con®rmation of HIT type II, such as PA [9] , HIPA [10] and PF4±heparin ELISA [6] . PA and HIPA detect HI-IgG and require fresh platelets. The variability of donor platelets, HLA cross-reaction between donor platelets and patient sample, and residual heparin in the sample reduce the usability of these assays and/or have a falsenegative result [10, 19] . PF4±heparin ELISA was developed on the hypothesis that PF4±heparin complexes are the major antigens involved in HIT type II [6, 7] . This assay has a speci®city of 80±95% and a sensitivity of 80±90% for HIT type II with 10±15% positive results in heparinreceiving patients without thrombocytopenia [6, 7, 20] . Recently, 17´3% (15/87) HIT patients were described lacking antibodies to PF4±heparin complexes but having autoantibodies to interleukin-8 (IL-8) or neutrophilactivating peptide-2 (NAP-2) [21] . Most recently, Chong and colleagues [22] reported a liquid phase enzyme immunoassay with protein G to capture HI-IgG in HIT sera and biotin-labelled PF4 as the signal carrier. This new assay detects anti-PF4±heparin IgG antibody too.
The HI-IgG assay imitates the natural interactions between HI-IgG and neoantigens of heparin complexes. The experiments using diluted or IgG-depleted HIT-type sera con®rmed that HI-IgG was responsible for the binding of FITC-heparin in the present assay system (data not shown). In preliminary experiments, the neoantigen was also prepared by incubating FITC-heparin with puri®ed PF4. There was no difference in the results when PF4 was used in pooled normal serum (data not shown). Therefore, FITC-heparin/serum solution was applied as the neoantigen in the present assay. HI-IgG showed good agreement with both HIPA (r 0´938) as well as clinical diagnosis of HIT-suspected patients (r 0´975).
The competitive HI-IgG assay determined the crossreactivities of HIT sera with LMWH and danaparoid, and had good agreement with the HIPA assay. The competitive studies demonstrated that mainly the IgG anti-heparin-PF4 antibodies are responsible for the cross-reactivity with LMWH and danaparoid.
Amiral [6] et al. reported that anti-PF4±heparin IgG antibody was present in about 80% of HIT patients. In the present study 97´7% (37/38) HIT patients had HI-IgG. A reason for the higher frequency detected may possibly be explained by the fact that HI-Abs against heparin/IL-8 or NAP-2, etc., could be detected by the HI-IgG assay [21] .
Positive results in other thrombocytopenic patients or heparin/LMWH-receiving patients as well as healthy persons were reported [6, 7, 23] . None of 38 other thrombocytopenic patients or 319 normal volunteers showed HI-IgG antibody (Fig. 1) . Two of 56 heparin/LMWH-receiving patients showed elevated HI-IgG ratios. Both patients did not develop thrombocytopenia and/or thromboembolism. They may be at high risk of developing HIT type II [6, 7] . The frequency of HI-IgG generation was 3´6% (2/56) in heparin/LMWH-treated patients without any complication, this is consistent with the observation of other investigators [6] . The time to disappearance of HI-IgG was 2±4 weeks after withdrawal of heparin is in agreement with a previous report [6] . A total of 4±5% of samples from patients with hyperlipidaemia showed false-positive results in the FLIFA, which is similar to other patient samples. Previous studies demonstrated variable in vitro crossreaction between HI antibodies with LMWH or danaparoid in the PA and HIPA assays [10, 24] . HIT type II sera also showed cross-reaction with LMWH and sometimes with danaparoid in the present assay. One of the four HIT sera with positive danaparoid cross-reaction in HIPA showed a negative result in the HI-IgG assay. The different techniques used by both assays may be the reason for this discrepancy. In fact, this patient was effectively treated with danaparoid and the platelet count was normalized within a few days. This actually supports the view expressed by Chong et al. [22] covering the clinical value of cross-reactivity detected by functional vs. immunoassays.
The HI-IgG assay reported here, to our knowledge, is the most rapid test to have been published. The combination of ®ltration and FluorImager techniques offers a considerable advance in speed. The relatively quantitative HI-IgG assay yields results in about 1 hour. This is a clinically important distinction [25] from the other tests, except the HIPA. In summary, HI-IgG assay provides a rapid and sensitive laboratory tool for con®rming the clinical diagnosis and studying the pathophysiology of HIT.
